Poxel SA: Leading the Charge in Type 2 Diabetes Treatment with Innovative Drug Development
Poxel SA is a pioneering biopharmaceutical company that is revolutionizing the treatment of Type 2 diabetes with its innovative drugs, including Imeglimin, a promising candidate in clinical phase 2 studies.
2 minutes to read